17123-74-9

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-Acetoxyphenyl)propionic acid is used as an analgesic and anti-inflammatory agent for the treatment of pain and inflammation associated with conditions such as rheumatoid arthritis and osteoarthritis. It is effective in reducing the synthesis of prostaglandins, which are key mediators of the inflammatory response, thus alleviating pain and swelling in affected areas.
Used in Pain Management:
3-(2-Acetoxyphenyl)propionic acid is used as a pain reliever to provide relief from mild to moderate pain, including that associated with headaches, muscle aches, and menstrual cramps. Its analgesic properties make it a suitable option for managing various types of pain.
Used in Inflammation Control:
3-(2-Acetoxyphenyl)propionic acid is used as an inflammation controller to reduce inflammation in various conditions. By inhibiting the synthesis of prostaglandins, it helps to decrease swelling and redness, providing relief from the symptoms of inflammation.

InChI:InChI=1/C11H12O4/c1-8(12)15-11(14)7-6-9-4-2-3-5-10(9)13/h2-5,13H,6-7H2,1H3

Upstream product

• 90-01-7 salicylic alcohol 
• 1318928-52-7 2-(3-hydroxypropyl)phenyl acetate 
• 1346808-84-1 2-(3-((tert-butyldimethylsilyl)oxy)propyl)phenol 
• 1481-92-1 2-(3-hydroxypropyl)phenol 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 495-78-3 3-(2-hydroxyphenyl)propionic acid 
• 75-36-5 acetyl chloride 

Downstream Products

• 1334231-05-8 (S)-2-((S)-6-(ethanethioamido)-2-(3-(2-hydroxyphenyl)propanamido)hexanamido)propanoic acid 
• 99854-11-2 β-(o-Acetoxy-phenyl)-propionyl-chlorid 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY

The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2

The lack of substrate-bound crystal structures of SIRT1 and SIRT2 complicates the drug design for these targets. In this work, we aim to study whether SIRT3 could serve as a target structure in the design of substrate based pseudopeptidic inhibitors of SIRT1 and SIRT2. We created a binding hypothesis for pseudopeptidic inhibitors, synthesized a series of inhibitors, and studied how well the fulfillment of the binding criteria proposed by the hypothesis correlated with the in vitro inhibitory activities. The chosen approach was further validated by studying docking results between 12 different SIRT3, Sir2Tm, SIRT1 and SIRT2 X-ray structures and homology models in different conformational forms. It was concluded that the created binding hypothesis can be used in the design of the substrate based inhibitors of SIRT1 and SIRT2 although there are some reservations, and it is better to use the substrate-bound structure of SIRT3 instead of the available apo-SIRT2 as the target structure.